Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Talarozole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 known ✓ | O43174 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 2/20 | 1.00 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Talarozole SCHEMBL21020998 | 1.00 | CYP26A1 (1.00) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| Talarozole SCHEMBL721201 | 1.00 | CYP26A1 (1.00) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| Talarozole SCHEMBL4984008 | 1.00 | CYP26A1 (1.00) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| SCHEMBL9005425 | 0.87 | CYP26A1 (0.77) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| SCHEMBL9005429 | 0.86 | CYP26A1 (0.76) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| SCHEMBL4986440 | 0.85 | CYP26A1 (1.00) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| SCHEMBL13642299 | 0.85 | CYP26A1 (0.73) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| SCHEMBL10000095 | 0.84 | CYP26A1 (0.73) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| SCHEMBL9005850 | 0.84 | CYP26A1 (0.73) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| SCHEMBL24259982 | 0.84 | CYP26A1 (0.72) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10039751-B2 | Reversing intestinal inflammation by inhibiting retinoic acid metabolism | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-08-07 | — | — | US | claimed |
| US-20170189384-A1 | REVERSING INTESTINAL INFLAMMATION BY INHIBITING RETINOIC ACID METABOLISM | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-07-06 | — | — | US | claimed |
| US-9623013-B2 | Reversing intestinal inflammation by inhibiting retinoic acid metabolism | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-04-18 | — | — | US | claimed |
| US-20160158206-A1 | Reversing Intestinal Inflammation by Inhibiting Retinoic Acid Metabolism | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-06-09 | — | — | US | claimed |
| US-9248120-B2 | Reversing intestinal inflammation by inhibiting retinoic acid metabolism | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-02-02 | — | — | US | claimed |
| US-7378433-B2 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-05-27 | — | — | US | claimed |
| EP-4083029-A1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | University of Washington through its Center for Commercialization (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-3044216-B1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-23 | — | — | EP | disclosed |
| US-10370644-B2 | Method for making human pluripotent suspension cultures and cells derived therefrom | JANSSEN BIOTECH, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10039751-B2 | Reversing intestinal inflammation by inhibiting retinoic acid metabolism | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-08-07 | — | — | US | disclosed |
| US-9963439-B2 | Specific inhibitors of cytochrome P450 26 retinoic acid hydroxylase | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170189384-A1 | REVERSING INTESTINAL INFLAMMATION BY INHIBITING RETINOIC ACID METABOLISM | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-07-06 | — | — | US | disclosed |
| US-9623013-B2 | Reversing intestinal inflammation by inhibiting retinoic acid metabolism | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-04-18 | — | — | US | disclosed |
| US-20140295552-A1 | SUSPENSION AND CLUSTERING OF HUMAN PLURIPOTENT STEM CELLS FOR DIFFERENTIATION INTO PANCREATIC ENDOCRINE CELLS | JANSSEN BIOTECH, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20140295552-A1 | SUSPENSION AND CLUSTERING OF HUMAN PLURIPOTENT STEM CELLS FOR DIFFERENTIATION INTO PANCREATIC ENDOCRINE CELLS | JANSSEN BIOTECH, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20130131129-A1 | Reversing Intestinal Inflammation by Inhibiting Retinoic Acid Metabolism | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2013-05-23 | — | — | US | disclosed |
| US-8399495-B2 | Talarazole metabolites | STIEFEL LABORATORIES, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120283204-A1 | TALARAZOLE METABOLITES | BARRETT DEBRA (US) | 2012-11-08 | — | — | US | disclosed |
| US-8188124-B2 | Talarazole metabolites | STIEFEL LABORATORIES, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100292284-A1 | Talarazole metabolites | STIEFEL LABORATORIES, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292284-A1 | Talarazole metabolites | UGT1A3, GRHPR, UGT1A7 | CYP26A1 29/4885CYP3A4 85/4885CYP2C9 52/4885 |
| US-20120283204-A1 | TALARAZOLE METABOLITES | UGT1A3, GRHPR, UGT1A7 | CYP26A1 29/4885CYP3A4 85/4885CYP2C9 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.